What are the guidelines for using aspirin (acetylsalicylic acid) in patients with impaired renal function?

Aspirin Use in Renal Impairment

Aspirin should be used with extreme caution in patients with renal impairment, with clear distinctions between secondary prevention (where benefits generally outweigh risks) and primary prevention (where aspirin is generally not recommended, particularly in moderate-to-severe CKD). 1

Secondary Prevention: Use Aspirin Despite Renal Impairment

For patients with established atherosclerotic cardiovascular disease (ASCVD), aspirin 75-162 mg daily should be continued regardless of renal function, as the cardiovascular mortality reduction far outweighs bleeding risk. 1, 2

• The American Diabetes Association and American Heart Association recommend aspirin 75-162 mg daily for all patients with prior myocardial infarction, stroke, or documented ASCVD, including those with chronic kidney disease 1
• In post-hoc analysis of patients with GFR <60 mL/min/1.73 m², aspirin 75 mg/day prevented 76 major cardiovascular events and 54 deaths per 1000 persons with GFR <45 mL/min/1.73 m², while causing 27 excess major bleeds 1
• For documented aspirin allergy, substitute clopidogrel 75 mg daily 1, 2

Primary Prevention: Generally Avoid in CKD

Aspirin for primary prevention is not recommended in patients with chronic kidney disease due to increased bleeding risk that offsets cardiovascular benefits. 1

• The 2013 KDIGO guidelines suggest offering antiplatelet agents only when atherosclerotic event risk outweighs increased bleeding risk 1
• Current guidelines recommend generally avoiding primary prevention with aspirin in CKD patients, particularly those with moderate-to-severe impairment 1
• The ongoing ATTACK trial (recruiting 25,210 CKD patients, completion 2025) will provide definitive evidence for primary prevention in this population 1

Specific Contraindications and High-Risk Scenarios

NSAIDs including aspirin are absolutely contraindicated in patients with cirrhosis and ascites due to high risk of acute renal failure, hyponatremia, and diuretic resistance. 1

• In cirrhotic patients with ascites, NSAIDs cause reduced renal perfusion secondary to inhibition of renal prostaglandin synthesis 1
• Aspirin should be avoided in patients with severe coagulopathy or disseminated intravascular coagulation 1

Bleeding Risk Assessment Algorithm

Before prescribing aspirin in renal impairment, systematically assess bleeding risk using these criteria:

• Age >70 years: Bleeding risk substantially increases, particularly in primary prevention 1
• GFR <45 mL/min/1.73 m²: Bleeding risk increases with declining renal function (trend P=0.08 in major trials) 1
• Anemia or bleeding disorders: Active exclusion criteria 1
• Concurrent medications: NSAIDs, anticoagulants, or corticosteroids significantly increase bleeding risk 1
• History of gastrointestinal ulcers or bleeding: Major contraindication 1

Dosing Recommendations in Renal Impairment

Use the lowest effective dose (75-81 mg daily) to minimize bleeding risk while maintaining efficacy. 1, 2

• Doses of 75-100 mg daily were effective in CKD trials without requiring adjustment for renal function 1
• The ADAPTABLE trial found no difference between 81 mg and 325 mg in cardiovascular outcomes, but lower doses minimize gastrointestinal bleeding 2
• No pharmacokinetic dose adjustment is required for aspirin based on creatinine clearance alone 3

Monitoring Requirements

Monitor renal function closely when initiating aspirin in elderly patients or those with baseline renal impairment. 4

• In elderly patients, low-dose aspirin (100 mg daily) decreased creatinine clearance by 19% and uric acid clearance by 17% after 2 weeks 4
• 67% of elderly patients maintained some degree of renal impairment even after aspirin withdrawal 4
• Patients with better baseline renal function, lower hemoglobin, and lower serum albumin are at higher risk for adverse renal effects 4
• Check serum creatinine and estimated GFR within 1-2 weeks of initiating aspirin in high-risk patients 4

Special Population: Nephrotic Syndrome

In nephrotic syndrome with serum albumin <32 g/L, assess both arterial and venous thromboembolism risk before considering aspirin. 1

• Use aspirin only if arterial thromboembolism risk is ≥20/1000 patient-years (calculated using Framingham risk score, eGFR, diabetes, previous arterial thromboembolism) AND bleeding risk is low 1
• If serum albumin <25 g/L with high venous thromboembolism risk, consider warfarin instead of aspirin 1
• This algorithm was developed for membranous nephropathy but may apply to other causes of nephrotic syndrome 1

Common Pitfalls to Avoid

• Do not prescribe aspirin for primary prevention in patients with GFR <45 mL/min/1.73 m² without compelling cardiovascular indications 1
• Do not assume aspirin is safe in elderly patients with "normal" creatinine—use Cockcroft-Gault equation to estimate true GFR 4
• Do not combine aspirin with other NSAIDs in any patient with renal impairment—this dramatically increases acute kidney injury risk 1
• Do not use aspirin in patients with cirrhosis and ascites under any circumstances 1

Emerging Evidence

• One observational study found aspirin associated with increased cardiovascular events in CKD patients with body weight <60 kg (HR 4.014), suggesting weight-based considerations may be important 5
• A small randomized trial (AASER study) showed aspirin reduced coronary events and slowed renal disease progression in CKD patients without prior cardiovascular events, but this requires confirmation in larger trials 6